Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and often confers a good prognosis. Though surgery is the gold standard of treatment, unresectable or metastatic disease can necessitate systemic therapy. Of systemic agents, there is increasing interest in the use of immunotherapies and targeted therapy. Further study into the driver mutations in cSCC has identified opportunities for targeted therapy. In this review, we discuss both current and investigational immune and molecular targets of therapy for cSCC.

中文翻译：

---

皮肤鳞状细胞癌的分子和免疫靶点

皮肤鳞状细胞癌 (cSCC) 是第二常见的皮肤癌，通常预后良好。虽然手术是治疗的金标准，但无法切除或转移的疾病可能需要全身治疗。在全身性药物中，人们越来越关注免疫疗法和靶向疗法的使用。对 cSCC 驱动突变的进一步研究确定了靶向治疗的机会。在这篇综述中，我们讨论了 cSCC 治疗的当前和研究性免疫和分子靶点。